Anika Therapeutics | ANIK - Current Assets


Anika Therapeutics reported $93.56M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
Agenus USD 95.28M 38.15M Mar/2026
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Anika Therapeutics USD 93.56M 9.8M Mar/2026
Arrowhead Research USD 1.84B 665.36M Mar/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Insmed USD 1.61B 181.04M Mar/2026
Integra LifeSciences USD 1.17B 12.47M Mar/2026
Intrexon USD 23.72M 45.04M Jun/2024
J&J USD 59.17B 3.55B Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Ligand Pharmaceuticals USD 865.42M 33.14M Mar/2026
MacroGenics USD 182.52M 37.42M Mar/2026
Merit Medical Systems USD 1.1B 61.62M Mar/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.16B 789M Mar/2026
Smith & Nephew USD 4.63B 169M Dec/2025
Stryker USD 13.34B 1.42B Mar/2026
Surmodics USD 75.99M 5.31M Jun/2025
Veracyte USD 522.17M 33.8M Mar/2026
Xencor USD 482.85M 116.97M Mar/2026
Zimmer Biomet Holdings USD 4.96B 157.4M Mar/2026